Avilar Therapeutics
PrivateLast Round
Seed
Feb 16, 2023
Total Funding Raised
$135M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Avilar Therapeutics is a biotechnology company that develops innovative extracellular protein degraders to target and eliminate disease-causing proteins from circulation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Avilar Therapeutics Comparables
Compare Avilar Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Draupnir Bio | 87% | |
| Lycia Therapeutics | 86% | |
| GlycoEra | 83% |
Avilar Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Feb 16, 2023 | ||||
| Seed | Nov 18, 2021 |
Avilar Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Seed |
| Medical Excellence Capital | Seed |
| Astellas Venture Management | Seed |
| Sanofi Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 20, 2026
Monthly visitors increased 39% MoM, reaching 2.3K.
- Feb 16, 2023
$15M round with participation from RA Capital Management.
Recent news
Latest coverage and updates
- attends_eventOct 8, 2026
Avilar Therapeutics, Inc. announces that preclinical data from its sFlt1 ATAC program for preeclampsia is featured in a poster at the 2nd Hamburg International Symposium on Maternal-Fetal Medicine in Germany on Oct 9th-10th '26.
- hiresOct 5, 2026
Avilar Therapeutics, Inc. appoints Leslie Meltzer, Ph.D. as Chief Executive Officer in Massachusetts on Oct 5th '26
- is_developingOct 5, 2026
Avilar Therapeutics, Inc. develops ATACs (ASGPR Targeting Chimeras) that use the liver’s ASGPR-mediated degradation pathway to selectively remove pathogenic extracellular proteins from circulation.
- has_issues_withAug 25, 2026
Avilar Therapeutics, Inc. had issues with trade secret misappropriation and breach of the confidentiality agreement on Mar 1st '23.
Avilar Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Avilar Therapeutics's valuation, stock price, and market status.
Is Avilar Therapeutics a public or private company?
Avilar Therapeutics is a private company.
What is the current stock price of Avilar Therapeutics?
Avilar Therapeutics is a private company, so its shares have no public market price. Caplight tracks Avilar Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Avilar Therapeutics worth (valuation)?
Valuation information for Avilar Therapeutics is not publicly available.
Can I buy Avilar Therapeutics stock?
Avilar Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Avilar Therapeutics's last funding round?
Avilar Therapeutics's most recent funding round was Seed on February 16, 2023.
Who are the main investors in Avilar Therapeutics?
Key investors in Avilar Therapeutics include RA Capital Management.
Will Avilar Therapeutics IPO soon?
No public IPO plans have been announced for Avilar Therapeutics.
How can I track Avilar Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Avilar Therapeutics's shares on secondary markets.